CTOs on the Move


 
Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nanomixdx.com
  • 2121, Williams Street
    San Leandro, CA USA 94577
  • Phone: 510.428.5300

Executives

Name Title Contact Details

Similar Companies

Advarra

Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster.

KBP Biosciences

At KBP we are consistently reminded that patient care is the end goal of what we do daily.

SERVICES Hospital Pharmacy Management and Consulting

SERVICES Hospital Pharmacy Management and Consulting is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivagen Pharmaceuticals, Inc.

Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.